Passamonti Francesco
Passamonti Francesco
University of Insubria, Varese, Italy
Email verificata su uninsubria.it
TitoloCitata daAnno
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics, F Passamonti, AS Buser, SS Teo, R Tiedt, JR Passweg, ...
New England Journal of Medicine 352 (17), 1779-1790, 2005
34742005
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ...
Blood 113 (13), 2895-2901, 2009
10142009
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi, R Marchioli, J Kutti, H Gisslinger, G Tognoni, C Patrono, ...
New England Journal of Medicine 350 (2), 114-124, 2004
9012004
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ...
Journal of Clinical Oncology 23 (30), 7594-7603, 2005
8952005
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and …
N Gangat, D Caramazza, R Vaidya, G George, K Begna, S Schwager, ...
J Clin Oncol 29 (4), 392-397, 2011
7362011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ...
Journal of Clinical Oncology 29 (6), 761, 2011
6782011
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and …
F Passamonti, F Cervantes, AM Vannucchi, E Morra, E Rumi, A Pereira, ...
Blood 115 (9), 1703-1708, 2010
6112010
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA …
MA Sanz, FL Coco, G Martın, G Avvisati, C Rayón, T Barbui, ...
Blood 96 (4), 1247-1253, 2000
6042000
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid …
G Finazzi, R Marchioli, V Brancaccio, P Schinco, F Wisloff, J Musial, ...
Journal of Thrombosis and Haemostasis 3 (5), 848-853, 2005
5282005
Cardiovascular events and intensity of treatment in polycythemia vera
R Marchioli, G Finazzi, G Specchia, R Cacciola, R Cavazzina, D Cilloni, ...
New England Journal of Medicine 368 (1), 22-33, 2013
5182013
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ...
Blood 98 (12), 3383-3389, 2001
4692001
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ...
The American journal of medicine 117 (10), 755-761, 2004
4582004
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ...
New England Journal of Medicine 372 (5), 426-435, 2015
4442015
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A Tefferi, TL Lasho, CM Finke, RA Knudson, R Ketterling, CH Hanson, ...
Leukemia 28 (7), 1472, 2014
3932014
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A Tefferi, E Rumi, G Finazzi, H Gisslinger, AM Vannucchi, F Rodeghiero, ...
Leukemia 27 (9), 1874, 2013
3882013
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for …
G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ...
Leukemia 22 (2), 437, 2008
3352008
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
T Barbui, J Thiele, F Passamonti, E Rumi, E Boveri, M Ruggeri, ...
J Clin Oncol 29 (23), 3179-3184, 2011
3302011
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, ...
Blood 111 (3), 1686-1689, 2008
3122008
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease …
F Passamonti, E Rumi, D Pietra, C Elena, E Boveri, L Arcaini, E Roncoroni, ...
Leukemia 24 (9), 1574, 2010
3012010
Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
T Barbui, G Finazzi, A Carobbio, J Thiele, F Passamonti, E Rumi, ...
Blood 120 (26), 5128-5133, 2012
2932012
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20